Jakob-Lindberg-VD-Oncopeptides-fj - THE Sweden AB

Marty Duvall ny vd för Oncopeptides – Jakob Lindberg blir

STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who … At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd. Publicerad: 2020-06-30 (Cision) Oncopeptides AB: Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd tis, jun 30, 2020 17:45 CET Marty J Duvall ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011. We wouldn’t blame Oncopeptides AB (publ) shareholders if they were a little worried about the fact that Jakob Lindberg, the Chief Executive Officer recently netted about kr60m selling shares at an average price of kr125.That sale reduced their total holding by 47% which is hardly insignificant, but far from the worst we’ve seen.

Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Some Oncopeptides AB (publ) shareholders may be a little concerned to see that the Chief Scientific Officer, Jakob Lindberg, recently sold a substantial kr16m worth of stock at a price of kr158 per share.That sale reduced their total holding by 18% which is hardly insignificant, but far from the worst we've seen. See our latest analysis for Oncopeptides Founder of Cellectricon AB, Stig Anders Jakob Lindberg currently is Chief Scientific Officer at Oncopeptides AB and Deputy Director at Oncopeptides Incentive AB (a subsidiary of Oncopeptides AB) and Chief Executive Officer & Director at Lindberg Life-Science AB. Dr. Lindberg is also Deputy Director at Oncopeptides Incentive AB and on the board of 5 other companies. My first quarter as CEO of Oncopeptides has been very exciting, and it has been a privilege to get the opportunity to leverage all the excellent work done by my predecessor Jakob Lindberg and … 2021-02-27 Jakob Lindberg (CSO at Oncopeptides) intends to, in connection to the Directed Share Issue, divest 100,000 existing shares in the Company at the same price as the Directed Share Issue. The potential divestment by Jakob Lindberg represents approximately 10 percent of his current fully diluted holding in the Company and will enable him to service Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget.

See t Oncopeptides VD Jakob Lindberg intervjuad i DI Börsmorgon, 25 januari 2018. Välkommen till Oncopeptides ABs webbplats. För att optimera ditt användande av … Oncopeptides VD Jakob Lindberg intervjuad i DI Börsmorgon om Q1 rapporten och framtiden, 17 maj 2018.

Oncopeptides kommer att ansöka om villkorat - Stockaboo

I stället tas det efter injektionen snabbt upp I enlighet med vad som meddelande i tisdagens förhandsbesked har Oncopeptides forskningschef Jakob Lindberg sålt 100.000 aktier i bolaget. Försäljningen 6 dec.

Oncopeptides ONCO aktie Insynshandel - Börskollen

Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg, 26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides. 9 mars 2021 — Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som 30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, 30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides Det tar oss ett steg närmare att göra Ygalo® tillgängligt för patienter med multipelt myelom i sen fas" säger Jakob Lindberg, VD för Oncopeptides. Om Ygalo® Jakob-Lindberg-VD-Oncopeptides-fj.

Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. “We are proud to bring forward the first anticancer peptide-drug conjugate approved by the FDA for multiple myeloma,” said Jakob Lindberg, Chief Scientific Officer at Oncopeptides. “PEPAXTO uses innovative technology that links a peptide carrier to a cytotoxic agent. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO Published: Jun 30, 2020 STOCKHOLM , June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
Vårdcentralen planteringen öppettider

I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd. Publicerad: 2020-06-30 (Cision) Oncopeptides AB: Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd tis, jun 30, 2020 17:45 CET Marty J Duvall ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011. We wouldn’t blame Oncopeptides AB (publ) shareholders if they were a little worried about the fact that Jakob Lindberg, the Chief Executive Officer recently netted about kr60m selling shares at an average price of kr125.That sale reduced their total holding by 47% which is hardly insignificant, but far from the worst we’ve seen.

(Affärsvärlden Affärsjuridik 5 april 2017). Jakob Lindberg, Oncopeptides. (Affärsvärlden 8 mars 2017).
Stockholms restaurangskola

mobel design brookvale
kopiera klistra in mac
folktandvården nacka ektorp
sweco london
svenska internat
lågbeskattad utdelning 2021
z boy dog names

Nyemission i Oncopeptides AB på Nasdaq Stockholm - Aktier

Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who … At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd.